Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) granted stock options covering 150,000 common shares to three new employees as a hiring inducement, effective November 17, 2026.
The options have a $1.00-per-share exercise price, equal to Geron’s closing share price on the grant date, and a ten-year term. They vest over four years, with 12.5% vesting six months after each employee starts and the rest vesting in equal installments of whole shares over the following 42 months. Vesting requires continued employment through each applicable vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Options on 150,000 common shares at $1.00 per share could dilute existing holders if exercised.
Key Figures
- Options granted
- 150,000 options
- Granted to three newly hired employees
- Exercise price
- $1.00 per share
- Equal to the closing price on the grant date
- Option term
- 10 years
- Term of the stock options
- Vesting period
- 4 years
- Subject to continued employment
- Initial vesting
- 12.5%
- Vests on the six-month anniversary of employment commencement
- Remaining vesting period
- 42 months
- Remaining shares vest in equal installments
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported that, effective November 17, 2026, it granted stock options to purchase an aggregate of 150,000 shares of common stock to three newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.
The stock options have an exercise price of
The equity awards were granted by the Compensation Committee of Geron’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the terms and conditions of Geron’s 2018 Inducement Award Plan and the form of stock option agreement under the plan.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
CONTACT:
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.